Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy
Researchers found PAM variants in about 10% of people may blunt GLP-1 blood sugar benefits, pointing to a need for genetic testing.
2 Articles
2 Articles
Stanford Study Identifies Why Ozempic and Wegovy Don't Work in About 1 in 10 Patients
A Stanford Medicine study identifies a genetic variant in about 10% of people that may reduce response to GLP-1 drugs like Ozempic and Wegovy, offering new insight into why these widely used diabetes and weight-loss treatments fail for some patients and highlighting the future of precision medicine in Type 2 diabetes care.
CANVA Ozempic and other medicines in the LPG-1 family have revolutionized the treatment of type 2 diabetes and weight loss. However, millions of patients have reported a disconcerting experience: while some people manage to control their glucose quickly, others barely observe results. Now, a new study led by Stanford Medicine researchers may have found an explanation. Scientists identified genetic variants that seem to cause a kind of “LPG-1 res…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
